Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
APH-1503
- Development stage
- Preclinical
- Lead developer
- Aphios Pharma
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Oral
01
Overview
APH-1503 is an extended-release cannabinoid nanoparticle formulation being developed by Aphios Pharma for the treatment of generalized anxiety disorder (GAD). The drug utilizes Aphios' patented SuperFluids Polymer Nanospheres (SFS-PNS) technology to encapsulate cannabidiol (CBD) within biodegradable polymer spheres. This formulation is designed for once-daily oral administration, providing controlled release and significantly improved bioavailability—approximately five times higher than standard CBD formulations. By protecting the active ingredient from gastric acid degradation and hepatic first-pass metabolism, APH-1503 aims to provide sustained relief from anxiety symptoms without the sedation or dependency risks associated with benzodiazepines and SSRIs. It is currently in preclinical development.
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)GPR12 (G protein-coupled receptor 12)GPR3 (G protein-coupled receptor 3)GPR55 (G protein-coupled receptor 55)GPR6 (G protein-coupled receptor 6)
Beyond the preview
Go deeper on APH-1503.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on APH-1503.